MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Natco Pharma Rolls Out a new Drug for Heart Ailment

Natco Pharma Rolls Out a new Drug for Heart Ailment

Natco Pharma, a Hyderabad-based pharmaceuticalcompany has rolled out a new drug for treating heart ailments. The new drug is known as Valsartan-sacubitril (under the company’s brand name Valsac).

Valsartan-sacubitril can eliminate the risk of cardiovascular death in patients suffering from congestive heart problem. It helps to relax the blood vessels. The same brand is sold as Entresto by another Pharmaceutical company, Novartis in the US and other countries.

According to a press release by Natco Pharma, 50 mg of Vymada will cost Rs. 45 and 100mg will cost Rs. 55.

As per the government’s app called Pharma Sahi Daam App, 14 tablets (24/26mg) will cost Rs. 977.50. While in the same price, there are other two tablets called Lupin and Cipla available in the market today.

The new launch by Natco Pharma has challenged the country’s largest drug makers, i.e. Novartis in terms of competition. Apart from that, there can be a battle of patents between the two companies since; Novartis sells the same drug under a different name in the US and other countries. In 2017, the drug’s sales were almost $500M and as per analyst, the sales may touch $2.2 billion by 2022.

Earlier, the two companies along with Cipla were engaged in a serious patent battle over an anti-cancer drug called Glivec.

“Novartis is aware that Natco has announced the launch of a generic version of valsartan-sacubitril and is currently evaluating its options,” quoted by a spokesperson for Novartis.

YOU MAY ALSO LIKE

Salesforce Expands into Thailand, Opens Office in Bangkok

Salesforce has announced permanent presence in Thailand by launching its new office in the country’s capital, Bangkok. The permanent presence wi...

GMLL is expected to soon add two more stores to its retail arm ‘Price Mantra’

Garment Mantra Lifestyle, a popular name in the Indian fashion retail segment, recently made an announcement that the company is expanding its retail ...

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

RECOMMENDED